Crohn disease (CD [MIM 266600]) is a severe chronic inflammatory bowel disease characterized by intestinal ulceration that affects predominantly the ileum and colon. 1, 2 The cause of the disease is unknown. Recent findings have suggested that the mucosal immunological reaction is directed against the resident bacterial flora rather than against tissue antigens. 3 This loss of tolerance to the normal flora may be due to a dysregulation of the gut mucosal immune response 4 or, alternatively, a break in the antibacterial barrier where microbiota can trigger a deleterious immune response. 5 CD appears to be a consequence of both genetic and environmental influences. The 50% concordance rate in MZ twins, who often exhibit the same phenotype, 6 suggests a rather balanced impact of genetic and such environmental factors as smoking 7, 8 or childhood hygiene. 9 During a genomewide search, several susceptibility loci and genes-including NOD2 (CARD15) (MIM 605956), 10, 11 DLG5 (MIM 604090), 12 and OCTN (MIM 604190 and 603377) 13 -have been found to be associated with CD. The best replicated is NOD2, which is involved in intracellular sensing of bacterial muramyl dipeptide, promi-nently expressed in macrophages and in particular small intestinal Paneth cells. 14, 15 Despite these significant advances, the multiple susceptibility loci and other genetic factors hitherto identified 16 do not satisfactorily explain the inheritance rates.
The clinical syndrome of CD is variable with respect to age at diagnosis, location (small and/or large intestine), and disease behavior (inflammatory, stricturing, or penetrating disease). Therefore, these behavior parameters were used in the Vienna classification, 17 recently modified in Montreal. 18 Location of disease involvement proved to be stable over time in individual patients, although the biological basis of small-versus large-intestinal involvement is unclear. NOD2 mutations have been shown to be predominantly associated with ileal disease and have been reported to be related to a relative lack of ileal Paneth-cell alpha-defensins HD-5 (MIM 600472) and HD-6 (MIM 600471). 19 Defensins are endogenous antibiotic peptides that form a chemical barrier at the epithelial surface, and their relative deficiency may lead to bacterial adherence to the mucosa, slow invasion, and secondary mucosal inflammation. 5, 20 In contrast to ileal disease, colonic CD is characterized by an impaired induction of the epithelial beta-defensins HBD-2 (MIM 602215), HBD-3 (MIM 606611), and HBD-4. [21] [22] [23] This relative deficiency of several beta-defensins is unlikely to be explained by multiple coincident mutations or other genetic alterations of all these genes. Detailed studies of the defensin locus on chromosome 8 have uncovered an extensive DNA copy number polymorphism (CNP) of a gene cluster, including, among others, the human beta-defensin genes HBD-2 (DEFB4), HBD-3 (DEFB103), and HBD-4 (DEFB104). 24 It has been shown that the number of gene copies is positively correlated with the expression of HBD-2 in leukocytes. 24 Since all these defensins were found to be coordinately underexpressed in colonic CD, 21 we hypothesized that this particular phenotype may be associated with a low beta-defensin gene cluster copy number. We therefore measured DNA copy number in the beta-defensin cluster in two independent cohorts with inflammatory bowel diseases and related it to mucosal HBD-2 gene expression.
Material and Methods

Patients
The patients from three separate cohorts received diagnoses, with use of the same standard criteria, in Cleveland, Stuttgart, and Vienna and were treated in specialized tertiary-care out-and inpatient centers. Patients gave their informed consent, and local ethics committees approved the study protocols. A small cohortof patients with colonic CD ( ) and healthy control indi-n p 10 viduals ( )-was recruited in Stuttgart. Their blood-derived n p 10 genomic DNA was subjected to the microarray analysis described below. The exploratory cohort was a surgical group of patients who underwent surgical resection at the Cleveland Clinic for treatment of ileal or colonic Crohn disease (table 1) . The confirmatory cohort were all whites with CD or ulcerative colitis (UC [MIM 191930]) who were treated at the Robert-Bosch-Hospital (Stuttgart) or the University Hospital (Vienna) (table 1). Diagnostic and (Vienna) classification criteria were the same at both European centers. 17 In this classification, L1 is defined as ileal disease only, L2 as colonic disease only, and L3 as ileal as well as colonic disease. Finally, the Stuttgart control group was combined with blood donors ( ), individuals unaffected by inflammatory n p 103 bowel disease who underwent surveillance colonoscopy (n p ), and 20 control individuals unaffected by intestinal disease 46 from Cleveland. All colonoscopies that included biopsies were performed on patients from the Stuttgart cohort.
Array CGH (Array-Based Comparative Genomic Hybridization) Analysis
DNA preparation, labeling, hybridization, and analysis procedures were performed as published elsewhere. 25, 26 In brief, genomic DNA from fresh-frozen blood obtained from 10 patients with colonic CD and from 10 healthy control individuals was isolated using the Blood and Cell Culture Kit (Qiagen) following the instructions of the supplier. Sample DNA and reference DNA (pooled DNA from six healthy individuals) were labeled differentially with use of the Bioprime Labelling Kit (Invitrogen) and were hybridized on a DNA microarray consisting of ∼8,000 genomic fragments covering the human genome at a resolution of ∼0.5 Mb. 27 For the beta-defensin locus at 8p23.1, all additional genomic fragments that were available at the time were added to the microarray to enhance the resolution in the region of interest. The chromosomal mapping information was based on the Ensembl Genome Browser release 36.35i (December 2005) . Arrays were scanned, and fluorescence intensities of all spots were filtered (intensity/local background 13; mean/median intensity !1.3; SD of genomic fragment log ratios !0.25) and were normalized blockwise. Chromosomal breakpoints delimiting regions of different copy number status were detected by GLAD (gain and loss analysis of DNA). 28 
Determination of HBD-2 Gene Copy Number
A TaqMan real-time PCR assay, specifically for amplification of genomic HBD-2, was established by using a specific set of amplification primers (forward 5 -CACCTGTGGTCTCCCTGGAA-3 ; reverse 5 -AGCTTCTTGGCCTCCTCATG-3 ) and a probe (6-FAM-ATGCTGCAAAAAG-MGB). Quantitative HBD-2 amplification data were normalized to ALB (albumin [MIM 103600]) as an internal reference gene, which was coamplified simultaneously in a singletube biplex assay. The primers and probe for HBD-2 were designed using Primer Express software, version 1.5 (Applied Biosystems). For albumin, we used the primers and probe that were published elsewhere. 29 Primers were purchased from MWG-Biotech, and probes were obtained from Applied Biosystems. Real-time PCR was performed using the ABI Prism 7700 sequence-detection system. Amplification reactions (25 ml each) were performed in triplicate with 20 ng of template DNA, 1# TaqMan Universal Master Mix buffer (Applied Biosystems), 300 nM of each primer, and 200 nM of each fluorogenic probe. Thermal cycling was initiated with a 2-min incubation at 50ЊC, followed by a first denaturation step of 10 min at 95ЊC and then by 40 cycles for 15 s at 95ЊC and for 1 min at 60ЊC. In each assay, a standard curve was recorded and a no-template control was included. To amplify HBD-2 and albumin in a one-tube biplex assay, limiting primer conditions were identified, to avoid competition of the two reactions. Quantification was performed by both the standard-curve method and the comparative C T (threshold cycle) method, as described elsewhere. 29 The assay was validated with a selection of DNA samples, genotyped elsewhere (kindly provided by E. J. Hollox, Nottingham, United Kingdom), that contained 3, 4, 5, and 7 HBD-2 gene copies. 24 
Real-Time Quantitative PCR
Frozen biopsies were disrupted in 1 ml of Trizol (Gibco BRL) until complete fragmentation occurred. Total RNA was extracted according to the supplier's protocol. RNA quality was determined by electrophoresis and was quantified by photometry. Subsequently, 2 mg of RNA was reverse transcribed with oligo-dT primers and 200 U Superscript (Gibco BRL), according to the routine procedure.
cDNA samples were subjected to real-time PCR as outlined elsewhere. 21 In brief, an aliquot corresponding to 50 ng of RNA was set up in a 20-ml reaction mixture containing 4 mM MgCl 2 , 0.5 mM of each primer (for HBD-2, forward 5 -ATCAGCCATGAGG-GTCTTGT-3 and reverse 5 -GAGACCACAGGTGCCAATTT-3 [annealing temperature 60ЊC; product 172 bp]; for HBD-3, forward 5 -TGAAGCCTAGCAGCTATGAGGATC-3 and reverse 5 -CCGCC-TCTGACTCTGCAATAA-3 [annealing temperature 62ЊC; product 128 bp]; for interleukin 8 [IL-8 (MIM 146930)], forward 5 -ATGACT-TCCAAGCTGGCCGTGGC-3 and reverse 5 -TCTCAGCCCTCTT-CAAAAACTTC-3 [annealing temperature touch down protocol 66ЊC-60ЊC; product 292 bp] [Sigma]) and 1# LightCycler-Fast-Start DNA Master SYBR Green I Mix (Roche Molecular Biochemicals) and was loaded in capillary columns. PCR was performed for 45 cycles in a LightCycler (Roche Molecular Biochemicals). After each cycle, fluorescence emission readings reflecting the increase in PCR products were monitored and analyzed using LightCycler software (Roche Molecular Biochemicals).
DNA Sequencing
Exons 1 and 2 of the HBD2 gene and ∼50 bp of adjacent noncoding regions were PCR amplified from genomic DNA and were sequenced on an Applied Biosystems 3100 capillary sequencer with use of Big-Dye chemistry. The sequences of the amplification and nested sequencing primers are available on request.
Statistics
Statistical comparisons of copy numbers of (1) ileal and colonic subsets in the Cleveland cohort as well as (2) patients with L1, L2, and L3 UC and (3) control individuals from the European collective were performed with the (two-sided) Mann-Whitney test. Additionally, Kruskal-Wallis analysis of variance of ranks, including post hoc assessment by Dunn's test, was performed to correct for multiple testing. Differences in copy number distribution among the clinical cohorts were assessed by the Pearson x 2 test, with continuity corrections. Again, the Mann-Whitney test was used to assess differences in HBD-2 mRNA expression with increasing HBD-2 gene copy numbers.
Results
Microarray Analysis
Using an array CGH with ∼8,000 genomic fragments covering the human genome, with an average resolution of ∼0.5 Mb, we screened 10 patients with colonic CD and 10 healthy control individuals for DNA copy number variations. No gross chromosomal aberrations were present in either group (data not shown), but we detected several known regions of CNP, such as the IGHG1 gene cluster at 14q32.33 (MIM 147100) (data not shown) or the amylase gene cluster at 1p21.1 (MIM 104700) ( fig. 1A) . Except for the beta-defensin gene cluster at 8p23.1 ( fig. 1B) , however, no region showed a bias toward copy number loss or gain in patients versus controls. In the Ensembl Genome Browser (release 36.35i), the beta-defensin cluster is shown to be organized as a pair of inverted repeats separated by a sequence gap (fig. 1C ). This probably represents the minimal size of the locus in humans. In the patient and control samples that showed copy number variation compared with the control DNA, the size of the variable region was always the same, covering ∼900 kb (megabase 7.1-8.0), including BAC clones RP11-278P18, RP11-1005B13, and RP11-52B19 (Clone Registry). This region contains both copies of the beta-defensin cluster but not the alpha-defensin cluster, as is shown for patient X1604 in figure 1C . When comparing the copy number profiles of the patient and control groups, it became evident that patients with CD, on average, seemed to have fewer copies than did healthy individuals. Relative to a DNA pool from 6 healthy control individuals, 8 of 10 patients with CD displayed small copy number losses, and none displayed copy number gains ( fig. 1D ). In control individuals, no such bias was observed ( fig. 1E ). The neighboring alpha-defensin gene cluster ( fig. 1C ), which mapped to megabase 6.76-6.90, and other beta-defensin-like loci-identified on chromosomal bands 6p12, 20q11.1, and 20p13 by sequence similarity search 30 -did not show any copy number variation in patients or control individuals (data not shown).
HBD-2 Gene Copy Numbers in Inflammatory Bowel Diseases
Our array CGH analyses clearly indicated that low DNA copy number at the main beta-defensin locus might be connected to CD; however, the size of this initial sample was much too small for reliable correlation analysis. Furthermore, whereas array CGH is extremely useful for wholegenome scans, its quantitative performance is suboptimal at loci that are rich in low copy number DNA repeats (LCRs), such as the beta-defensin cluster. At such loci, the reported copy number ratios can be severely affected by cross-hybridization of the LCRs. 25 Therefore, we decided, as an alternative, to use quantitative PCR analysis of the HBD-2 gene to estimate the DNA copy number of the beta-defensin cluster. This HBD2 gene-specific approach was applied to a control population and to two patient cohorts, one from the United States and one from Europe (table 1). In the control population ( ) the copy numbers had a range of 2-10 n p 169 per genome, with a median number of 4 copies ( fig. 2A ). The numbers of control individuals who carry the median (4), below-median (!4), or above-median (14) number of copies were about equal. Details of the copy number frequencies of all cohorts and subgroups are given in table 2.
The U.S. patient cohort from the Cleveland Clinic consisted of 85 surgical patients with CD who had indications for ileal versus colonic resection. In patients with ileal resections ( fig. 2B) , the median number of copies was identical to that of the control group (4 copies); also, the frequency distribution of the three subgroups (with !4, with 4, and with 14 gene copy numbers) was not significantly different from that of the control group. In contrast, the majority (72%) of patients with colonic resections had a copy number !4, with a median of 3 copies (fig. 2C) . The difference in copy numbers was highly significant (P p [Mann-Whitney]) between the ileal and colonic sub-.008 groups with CD. This was maintained when tested by Kruskal-Wallis analysis of variance ( for both post P ! .01 hoc Dunn test ileal vs. colonic and colonic vs. control). Similarly, the proportion of the three copy number groups in the two subgroups with CD was significantly different (
[Pearson x 2 ]). P p .018
An independent second cohort of European patients with CD ( ) from Stuttgart and Vienna was classified ac-n p 165 cording to the Vienna classification of location into those with ileal disease only (L1), with colonic disease only (L2), or with ileal plus colonic disease (L3). Again, ileal CD (L1) exhibited a copy number distribution similar to controls ( ), with a majority in the group with 4 gene copies P 1 .05 ( fig. 3 ). The median was 4 copies in L1 and controls compared with 3 in L2 ( and , respectively P p .032 P p .001 [Mann-Whitney]). Analysis of variance and post hoc test identified a significant difference between L2 and controls 
only (
). Colonic CD only (L2) was characterized by P ! .05 a shift to lower copy numbers, with the majority (52%) carrying !4 copies of HBD-2 ( vs. controls; P p .002 P p vs. L1 [Pearson x 2 ]). Individuals with р3 copies have .037 a significantly higher risk of developing colonic CD than do individuals with у4 copies (odds ratio 3.06; 95% CI 1.46-6.45). Patients with L3 showed an intermediate distribution pattern between controls and L2, and, although the median was the normal 4 copies, the shift in distri-bution was significant ( [Mann-Whitney]). In UC, P p .034 differences with controls were not significant. Detailed noncategorized copy number data are given in table 2.
HBD-2 Expression Related to HBD-2 Gene Copy Numbers in Inflamed Mucosa
Mucosal biopsies were analyzed for HBD-2, HBD-3, and IL-8 expression in patients from the Stuttgart cohort. Since HBD-2 expression is negligible in normal mucosa but is enhanced during inflammation, the biopsy samples were taken from a subgroup of 44 patients with inflammation due to CD ( ) or UC ( ). HBD-2 and HBD-3 n p 17 n p 27 expression was highly correlated ( in CD; r p 0.84 r p in UC). When the mucosal mRNA expression of HBD-0.86 2 was related to the HBD-2 gene copy number in the same patients ( fig. 4) , HBD-2 mRNA expression was significantly diminished in the group with !4 compared with 4 copies (
[Mann-Whitney]) or у4 ( ), whereas IL-P p .023 P p .033 8 expression in these copy number groups was not significantly different (data not shown).
HBD-2 Gene Sequencing
Finally, to investigate the possibility that HBD-2 gene expression might be affected by the presence of gene copies that are inactivated by point mutations, we sequenced exon 1 and exon 2 of the HBD-2 gene in eight patients with colonic CD and eight control individuals. We did not find any nonsense or missense mutations in the coding region. The only sequence variations present were one synonymous SNP in exon 2 (rs2740090) and four SNPs in noncoding sequences (rs2740086, rs2740091, rs2737912, and rs2737913). These SNPs occurred without predominance in either patients or control individuals (data not shown; SNPs were retrieved from dbSNP).
Discussion
CNPs and their effect on phenotypic variation and disease recently have become a major focus of attention. [31] [32] [33] At present, 1200 loci of large-scale CNPs have been detected using BAC arrays (Clone Registry) 32, 33 or oligonucleotide arrays. 31 With use of SNP genotyping data, recent studies have found ∼1,000 fine-scale deletion variants in the human genome. [34] [35] [36] The role of these genetic alterations and their impact on disease or disease susceptibility is not clear. Several examples show that copy number alterations can lead to altered gene expression and disease; for example, copy number increase at the alpha-synuclein locus (4q21 [MIM 163890]) causes Parkinson disease (MIM 168600), 37 and duplication of PMP22 (17q11.2 [MIM 601097]) causes Charcot-Marie-Tooth disease (MIM 118220). 38 Recently, a study showed that some cases of early-onset Alzheimer disease (MIM 104300) resulted from a duplication of the APP locus (MIM 104760). 39 CNPs can also lead to disease susceptibility, which was shown, for example, for the possession of a low copy number of the CCL3L1 gene (MIM 601395) that is associated with markedly enhanced HIV/ AIDS (MIM 609423) susceptibility. 40 Gene CNPs, which are associated with variable drug response, have also been described for drug-metabolizing enzymes. For example, inherited amplification of an active gene in the cytochrome P450 CYP2D locus is a cause of ultrarapid metabolism of debrisoquine. 41 We have recently reported the development of an RT-PCR-based assay to genotype CYP2D6 (MIM 124030) with respect to its gene copy number, 29 similar to the technique used in the present study. A previous study of beta-defensin gene copy number in cystic fibrosis (MIM 219700) had negative results. 42 Recently, the finished sequence and a gene catalogue of chromosome 8 were reported. 43 A unique feature of the chromosome is a vast region of ∼15 Mb on distal 8p that appears to have a strikingly high mutation rate. Within this region, the CNPs in the defensin cluster on chromosome 8p23.1 are of special interest, since they may be linked to immune function and disease. The copy number variation in this region is complex, with two different clusters of defensins-alpha-and beta-defensins-apparently showing an independent variation of their copy numbers. 44 In the alpha-defensin cluster, the genes DEFA1 (MIM 125220) and DEFA3 (MIM 604522) code for the neutrophil defensins HNP-1 and HNP-3, respectively. Their copy numbers, with a range of 5-14, were related to neutrophil HNP 1-3 levels. 44 In contrast, copy numbers of DEFA5 (MIM 600472) and DEFA6 (MIM 600471)-coding for the alpha-defensins HD-5 and HD-6, respectively-appear to be stable, with two per diploid genome. 44 This was also confirmed for the patients with CD, which suggests that the low HD-5 and HD-6 levels in ileal CD are not related to low copy numbers. 45 Prompted by the diminished induction of beta-defensins in the colonic mucosa of patients with CD compared with patients with UC, [21] [22] [23] we asked whether the copy numbers in the variable beta-defensin locus were low with respect to those in both healthy control individuals and subjects with inflammatory bowel disease (UC and ileal CD). The initial experiments, with use of high-resolution array CGH for genomic copy number profiling, suggested that, compared with controls. there indeed was a lower copy number of the beta-defensin locus in patients with colonic CD. All other regions of CNPs covered by the microarray showed equal copy number distributions between patients with colonic CD and control individuals. A se- quencing approach of the HBD-2 gene in a limited number of patients with colonic CD and control individuals revealed several known SNPs but no nonsense or missense mutations. None of the SNPs was preferentially found in either patients or control individuals. Further haplotype analysis of the HBD-2 gene was not performed because of the immense difficulties of such analyses. 46 It might seem surprising that the beta-defensin locus on chromosome 8 has not been identified in any of the previous linkage studies, 10, 11 in particular since deletions recently were shown to be in linkage disequilibrium with SNPs. 35 The relevance of this finding for the present study is questionable, however, since the beta-defensin cluster consists of multiple gene copies and is expected to be much less stable than a simple deletion. Therefore, it is not clear whether gene CNPs are at all detectable by linkage analyses. Furthermore, previous studies might have overlooked a possible linkage, since they did not distinguish colonic and ileal CD.
Since DNA microarrays allow full coverage of the human genome but are less suitable for high-throughput studies in large patient cohorts, we developed a real-time PCRbased technique to quantitate HBD-2 copy number variations. Since HBD-2 and HBD-3 copy numbers covary in tandem, it may be assumed that the measured HBD-2 copy number reflects the whole beta-defensin gene cluster. 24, 44 This is also consistent with the close correlation of HBD-2 and HBD-3 expression demonstrated in the present and a previous study. 21 A similar PCR-based technique was recently published by Chen et al. 47 The normal median number of 4 copies found in the present study confirms the finding of Chen et al. 47 and that of Hollox et al. 42 but is slightly lower than the median of 5 observed by Linzmeier et al. 44 Since the surgical patients with CD usually have a par-ticularly severe disease course, we first studied patients with ileal versus colonic resections as typical phenotypes. A clear-cut difference by 1 gene copy was observed and was then confirmed in a second, larger cohort of patients classified clinically according to the Vienna classification. 17 We focused on localization as a stable factor during the disease course and noted that the patient cohort with colonic disease experienced a shift to lower copy numbers. Although this shift was significant, there was clearly an overlap between the groups, which suggests that additional, still unknown factors of genetic or environmental origin impact CD. Interestingly, patients with both ileal and colonic CD (L3) had an intermediate copy number distribution.
Notably, this relatively small difference in HBD-2 copy numbers appeared to have an influence on mucosal HBD-2 expression by gene dosage effect, 48 which was significantly higher in patients with 4 compared with those with fewer gene copies. The biological consequence will likely be an impaired antimicrobial defense in individuals with !4 copies. This is consistent with the previous finding of Hollox et al. 24 that HBD-2 expression in lymphoblastoid cell lines was correlated linearly with the HBD-2 gene copy number in the range of 2-7 copies. In some contrast, we did not observe a linear increase in the higher range of copy numbers 14, which may be related to the present complex patient situation in which many other factors, including bacterial flora and inflammation, may affect defensin expression. Alternatively, the plateau in defensin gene expression we observe at copy numbers of у4 might be due to some unknown mechanism limiting gene expression in the native colon tissue, which might not be active in lymphoblastoid cells. At any rate, despite these confounding factors, the gene dosage effect on HBD-2 expression prevailed for low-to-normal copy numbers.
In conclusion, the low beta-defensin gene copy number in CD was clearly associated with colonic disease localization-that is, a specific phenotype of CD. A normal betadefensin copy number distribution was seen in CD of the ileum and also in UC. This study may provide the genetic basis for the diminished induction of beta-defensins in colonic CD compared with UC in which colonic betadefensin induction is intact, as described elsewhere. [21] [22] [23] We suggest that the antibacterial barrier in the colonic mucosa is weakened because of relative defensin deficiency in colonic CD. This finding complements our previous report of a diminished alpha-defensin synthesis in ileal CD, which was further pronounced with a concomitant NOD2 mutation. 19, 45 This differential compromise of the complex defensin system may explain the different phenotypes of colonic versus ileal CD 20, 49 as well as the observation that bacteria of the normal flora adhere and sometimes invade the epithelium in CD. [50] [51] [52] Possibly, this barrier problem triggers the chronic inflammation known as CD.
